Regeneron Pharmaceuticals (REGN) Capital Expenditures (2009 - 2026)

Regeneron Pharmaceuticals has reported Capital Expenditures for 18 years, with the latest figure at $230.6 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 0.57% year-over-year to $230.6 million; the trailing twelve-month figure through Mar 2026 stood at $899.7 million (up 5.69% YoY), and the FY2025 full-year result was $898.4 million, up 18.85% from the prior year.
• Capital Expenditures for Q1 2026 stood at $230.6 million, down from $248.7 million in the prior quarter.
• The five-year high for Capital Expenditures was $470.9 million in Q3 2025, with the low at -$102.8 million in Q2 2023.
• Average Capital Expenditures over 5 years is $187.9 million, with a median of $178.2 million recorded in 2023.
• Year-over-year, Capital Expenditures soared 174.95% in 2023 and sank 385.31% in 2025.
• Tracing REGN's Capital Expenditures over 5 years: stood at $152.2 million in 2022, then soared by 65.18% to $251.4 million in 2023, then declined by 20.6% to $199.6 million in 2024, then gained by 24.6% to $248.7 million in 2025, then fell by 7.28% to $230.6 million in 2026.
• The last three Capital Expenditures figures came in at $230.6 million (Q1 2026), $248.7 million (Q4 2025), and $470.9 million (Q3 2025), per Business Quant data.

Peer Comparison